Sleep research review

Treatments for Sleep Apnea: A Research Review

Published November 2026

Sleep apnea treatment should make breathing safer and sleep more restorative, not simply quiet the snoring. Several treatments work, but they are not interchangeable. The right choice depends on the type of apnea, test results, symptoms, health conditions and what you can use consistently. This review focuses on adult treatment evidence; our existing sleep-apnea and sleep-study guides explain symptoms and diagnosis. [1, 2]

Start with the type of apnea

Obstructive sleep apnea (OSA) involves repeated upper-airway narrowing or blockage. Central sleep apnea (CSA) involves disrupted control of breathing. Some people have both. A treatment that holds the throat open does not necessarily correct a problem with breathing control. Confirming the diagnosis comes before choosing a device or comparing products. [1]

Researchers commonly measure the apnea-hypopnea index (AHI), the number of qualifying breathing events per hour of sleep. A lower AHI matters, but so do oxygen levels, daytime sleepiness, functioning, comfort and sustained use. A large percentage improvement is not automatically a cure: a high starting AHI can fall substantially while clinically important apnea remains. [2, 8]

Positive airway pressure has the strongest routine role

PAP uses air pressure delivered through a mask to keep the airway open. CPAP delivers a set pressure; APAP adjusts within prescribed limits. The American Academy of Sleep Medicine (AASM) strongly recommends PAP for adults with OSA and excessive sleepiness, and conditionally recommends it for impaired sleep-related quality of life or coexisting high blood pressure. Bilevel machines are useful in selected circumstances, but are not automatically better than CPAP or APAP for routine OSA. [2]

Benefits depend on using treatment during sleep. Mask leaks, dryness, congestion or a claustrophobic feeling are problems to troubleshoot, not evidence that you have failed. Ask about fit, a different mask, humidification and clinician-guided settings. Follow-up should examine both symptoms and device data. [3]

Heart-health claims need care. In the large SAVE randomized trial, CPAP did not reduce major cardiovascular events in people with established cardiovascular disease, moderate-to-severe OSA and mostly minimal daytime sleepiness; average use was 3.3 hours nightly. Sleepiness and quality of life improved. That result does not erase PAP’s breathing and symptom benefits, or prove that all-night use has no cardiovascular benefit. It does mean prevention of heart attacks or strokes should not be promised. [4]

An oral appliance can be a practical alternative

A custom, adjustable oral appliance usually advances the lower jaw to reduce airway collapse. AASM and dental-sleep guidelines support it for adults with OSA who cannot tolerate CPAP or prefer an alternative. CPAP generally reduces breathing events and oxygen disturbances more effectively, while oral appliances can also improve sleepiness and quality of life. The most useful option must be both effective and usable. [5]

A qualified dentist and sleep clinician should coordinate treatment. Ordinary sports mouthguards are not equivalent. Jaw discomfort, dental changes and bite changes need monitoring, and follow-up sleep testing checks whether the appliance actually controls apnea. Less snoring alone is not enough. [5]

Position and weight matter for some people

Positional therapy aims to reduce back-sleeping when testing shows that OSA is substantially worse in that position. A randomized trial of a vibrating positional device in carefully selected positional OSA found benefit, but APAP produced a lower residual AHI. This is an option for an identified pattern, not proof that side-sleeping treats everyone’s apnea. Effectiveness and continued use still need checking. [6]

For people who are overweight or have obesity, supported weight management can reduce OSA severity and improve broader health. The American Thoracic Society recommends an individualized program combining nutrition, activity and behavioral support; medication or bariatric surgery may suit selected patients. Weight is not the only cause, and treatment should not be withheld while someone works on it. Improvement does not establish that PAP can be stopped without reassessment. [7, 3]

A medication option for a specific group

In the United States, tirzepatide, sold as Zepbound, is approved for moderate-to-severe OSA in adults with obesity, alongside a reduced-calorie diet and increased physical activity. It is not an approval for all sleep apnea or for central apnea. Suitability requires a prescriber’s review of contraindications, other medicines and adverse effects, including serious risks; gastrointestinal symptoms are common. [9, 13]

Two 52-week randomized trials, involving 469 adults, studied people not using PAP and people already using PAP. Compared with placebo, tirzepatide reduced AHI by about 20 and 24 additional events per hour, respectively, and improved several sleep-related outcomes. PAP users paused PAP before outcome testing; the results do not establish when it is safe to stop PAP. These are meaningful results, not a guarantee of remission. The studies were manufacturer-funded and did not establish outcomes beyond one year or what happens after stopping treatment. Do not discontinue PAP simply because weight or symptoms improve. [8, 13]

Surgery and stimulation need careful selection

Surgical consultation can be appropriate when PAP is unacceptable or difficult to use despite support. Options include selected throat procedures, tonsil removal or moving the jaws forward. Results depend on the anatomy and procedure; a consultation is a discussion, not a commitment to surgery. The AASM generally recommends trying PAP first, including for many adults with an anatomical obstruction, while allowing individualized exceptions. [10]

Hypoglossal nerve stimulation uses an implanted device to activate tongue-related muscles during sleep. It can help selected people with OSA who cannot use PAP successfully, but eligibility depends on the sleep-study findings, airway-collapse pattern and device labeling. Implant surgery, programming, follow-up and possible further procedures are part of the decision. It is not a universal replacement for CPAP or a treatment for predominantly central apnea. [11]

Central apnea needs a different plan

CSA treatment starts with its cause, including optimizing contributing illnesses and reviewing medicines such as opioids with the prescriber. The 2025 AASM guideline conditionally supports selected uses of CPAP, bilevel PAP with a backup breathing rate, adaptive servo-ventilation (ASV), oxygen, acetazolamide and implanted phrenic nerve stimulation. Evidence certainty varies, and these options apply to different causes; ordinary bilevel without a backup rate is discouraged. [12]

ASV requires specialist assessment, particularly with heart failure. Heart function and device-specific contraindications must be reviewed. The guideline limits ASV treatment in reduced-ejection-fraction heart failure to experienced centers with close monitoring. The goal includes better symptoms and quality of life, not merely eliminating a number on a recording. [12, 14]

Make follow-up part of treatment

Ask your clinician: What type of apnea do I have? Which outcomes are we trying to improve? How will we confirm this treatment works? What happens if I cannot use it? Regular review can identify leaks, persistent events or another cause of ongoing sleepiness. Repeat testing may be needed after a substantial weight change or a change in treatment. Do not drive when sleepy. [3, 15]

The best plan is not necessarily the newest product. It is a treatment matched to your breathing problem, used consistently and checked for benefit. Bedtime habits can support sleep, but should complement rather than replace effective apnea care.

Sources and further reading

More from MySleepCure

← Back to Rest Well Journal practical explainers